$PHVS

Schikan Johannes Gerardus Christiaan Petrus sold $84K of PHVS

Schikan Johannes Gerardus Christiaan Petrus sold 2,400 shares of Pharvaris N.V. (PHVS) at $35.10 on 2026-06-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Schikan Johannes Gerardus Christiaan Petrus
Published Jun 29, 2026, 10:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 10:20 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PHVS
Neutral
high confidence
Mentioned
$PHVS
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

A director’s pre-arranged open-market sale is typically low-signal for fundamentals; traders may only adjust short-term sentiment or monitor for future non-10b5-1 activity.

02

Market read

Disclosed insider selling amount ($84.25K) is modest and explicitly pre-arranged, implying limited trading edge.

03

What to watch

Insider sales under 10b5-1 can be scheduled regardless of company outlook; the filing doesn’t include any new operational or clinical catalyst.

Relevance 2/10Novelty 3/10Timing: filed 2026-06-29 (after-hours) for a same-day 10b5-1 sale

Background

The article is an SEC Form 4 insider transaction disclosure for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralHigh confidence
Context

SEC Form 4 shows director Schikan sold 2,400 PHVS shares on 2026-06-29 under a pre-arranged 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No sector read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale may be purely liquidity/tax-driven under the 10b5-1 plan, so it shouldn’t be treated as a bearish fundamental signal.

Key entities

  • Pharvaris N.V.

    Company subject of the Form 4 insider transaction disclosure.

  • Schikan Johannes Gerardus Christiaan Petrus

    Director who sold 2,400 shares on 2026-06-29 under a 10b5-1 plan.

Related articles

MedAI 8/10

Pharvaris Gains FDA Acceptance For Deucrictibant In Hereditary Angioedema

Pharvaris N.V. (PVHS) said the U.S. FDA accepted its NDA for deucrictibant immediate-release 20 mg capsules for on-demand treatment of hereditary angioedema attacks. A PDUFA action date is April 23, 2027. The submission cites Phase 3 RAPIDe-3 results (median onset 1.28 hours; complete resolution 11.95 hours; >1,300 attacks; primary and 11 secondary endpoints met).